- Home
- KEYS vs TAK Comparison
KEYS vs TAK Comparison
Compare KEYS & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KEYS | TAK |
|---|---|---|
| Founded | 1939 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2B | 56.6B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | KEYS | TAK |
|---|---|---|
| Price | $346.66 | $16.64 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $287.00 | N/A |
| AVG Volume (30 Days) | 916.7K | ★ 3.0M |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.17% |
| EPS Growth | ★ 39.89 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $5,375,000,000.00 | N/A |
| Revenue This Year | $25.49 | $0.16 |
| Revenue Next Year | $8.17 | $1.22 |
| P/E Ratio | $212.62 | ★ $41.25 |
| Revenue Growth | ★ 7.95 | N/A |
| 52 Week Low | $140.73 | $12.99 |
| 52 Week High | $348.43 | $18.90 |
Technical Indicators
Market Signals| Indicator | KEYS | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 74.88 | 29.79 |
| Support Level | $270.75 | $15.63 |
| Resistance Level | N/A | $18.74 |
| Average True Range (ATR) | 7.96 | 0.22 |
| MACD | 1.63 | -0.19 |
| Stochastic Oscillator | 90.38 | 4.08 |
Price Performance
Historical ComparisonAbout KEYS Keysight Technologies Inc.
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.